Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 6/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421432 | 0.90 | DYRK1A (0.55) | DYRK1AKCNH2GSK3BPIK3C3GSK3A | |
| SCHEMBL25420888 | 0.88 | DYRK1A (0.53) | DYRK1AKCNH2GSK3BPIK3C3ABL1 | |
| SCHEMBL30461615 | 0.88 | DYRK1A (0.53) | DYRK1AKCNH2GSK3BPIK3C3ABL1 | |
| SCHEMBL25421304 | 0.87 | PIK3C3 (0.57) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL30461584 | 0.87 | DYRK1A (0.53) | DYRK1AKCNH2GSK3BPIK3C3GSK3A | |
| SCHEMBL30461674 | 0.86 | DYRK1A (0.41) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL25421481 | 0.86 | DYRK1A (0.41) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL30461671 | 0.82 | PIK3C3 (0.56) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL25422264 | 0.80 | DYRK1A (0.61) | DYRK1AKCNH2GSK3BPIK3C3ABL1 | |
| SCHEMBL30461629 | 0.78 | GPR119 (0.43) | DYRK1AKCNH2GSK3BPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | DYRK1A 2/4885KCNH2 3337/4885GSK3B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.